InvestSMART

Anteris Technologies Ltd (ASX: AVR) - Announcements

Current share price for AVR : $11.100 0.08 (0.73%)+

ASX company news and announcements for Anteris Technologies Ltd (AVR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Anteris Technologies Ltd (AVR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Anteris Technologies Ltd (AVR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Anteris Technologies Ltd (AVR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$162 Notification regarding unquoted securities - AVR 24 Jun 2026 4:35PM $15.000 $11.100 fallen by 26%
$162 Application for quotation of securities - AVR 24 Jun 2026 4:30PM $15.000 $11.100 fallen by 26%
$162 Change of Director's Interest Notice 22 Jun 2026 9:47AM $13.320 $11.100 fallen by 16.67%
$162 PARADIGM - French Regulatory Clearance 9 Jun 2026 8:31AM $13.800 $11.100 fallen by 19.57%
$162 Change of Director's Interest Notice 5 Jun 2026 11:45AM $13.500 $11.100 fallen by 17.78%
$162 Statement of CDIs on issue - AVR 5 Jun 2026 11:43AM $13.500 $11.100 fallen by 17.78%
$162 Notification of cessation of securities - AVR 2 Jun 2026 6:04PM $12.500 $11.100 fallen by 11.20%
$162 Prospectus Supplement and Sales Agreement 25 May 2026 8:53AM $12.910 $11.100 fallen by 14.02%
$162 Initial Director's Interest Notice x 2 18 May 2026 2:58PM $9.790 $11.100 risen by 13.38%
$162 Board Appointments 13 May 2026 9:50AM $8.590 $11.100 risen by 29.22%
$162 Results for the First Quarter of 2026 13 May 2026 8:30AM $8.590 $11.100 risen by 29.22%
$162 Quarterly Results Announcement and SEC Form 10-Q 13 May 2026 8:22AM $8.590 $11.100 risen by 29.22%
$162 First US Patients Treated in Global Pivotal PARADIGM Trial 6 May 2026 9:04AM $8.330 $11.100 risen by 33.25%
$162 Statement of CDIs on issue - AVR 5 May 2026 11:55AM $8.200 $11.100 risen by 35.37%
$162 Termination of a Material Definitive Agreement 30 Apr 2026 9:31AM $7.500 $11.100 risen by 48%
$162 Notification regarding unquoted securities - AVR 29 Apr 2026 4:50PM $7.500 $11.100 risen by 48%
$162 Notification of cessation of securities - AVR 29 Apr 2026 4:48PM $7.500 $11.100 risen by 48%
$162 CMS Reimbursement Secured for PARADIGM Trial 28 Apr 2026 4:32PM $7.550 $11.100 risen by 47.02%
$162 Notification regarding unquoted securities - AVR 27 Apr 2026 2:58PM $7.600 $11.100 risen by 46.05%
$162 Entry into a Material Definitive Agreement 24 Apr 2026 9:12AM $7.560 $11.100 risen by 46.83%
$162 Notification regarding unquoted securities - AVR 14 Apr 2026 2:43PM $8.480 $11.100 risen by 30.90%
$162 Application for quotation of securities - AVR 13 Apr 2026 12:37PM $7.850 $11.100 risen by 41.40%
$162 Statement of CDIs on issue - AVR 7 Apr 2026 3:26PM $7.550 $11.100 risen by 47.02%
$162 Notification of cessation of securities - AVR 1 Apr 2026 7:13PM $7.880 $11.100 risen by 40.86%
$162 Notification regarding unquoted securities - AVR 12 Mar 2026 12:56PM $9.100 $11.100 risen by 21.98%

26 - 50 of 715 results

Page 2 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.